BLAINJECTIONINJECTABLE
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SIMLANDI (adalimumab-ryvk) by Alvotech is tnf-alpha and block its interaction with the p55 and p75 cell surface tnf receptors. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMLANDI is an adalimumab biosimilar (TNF-alpha inhibitor) approved by the FDA in February 2024. It blocks TNF-alpha interaction with p55 and p75 cell surface receptors, reducing inflammatory responses in autoimmune conditions. The drug is administered by injection and treats rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis.
Growth
Early-stage biosimilar in growth phase with commercial infrastructure build-out; expect expanding sales teams and operational staffing.
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SIMLANDI offers career opportunities in manufacturing quality assurance, regulatory compliance, and pharmacovigilance as Alvotech scales commercial operations. The biosimilar launch and high competitive pressure create demand for operational specialists, supply chain expertise, and market access professionals rather than traditional brand management roles.
Worked on SIMLANDI at Alvotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.